XML 6 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2025
Apr. 17, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K/A    
Document Annual Report true    
Amendment Flag true    
Document Period End Date Dec. 31, 2025    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Entity Registrant Name Terns Pharmaceuticals, Inc.    
Entity Central Index Key 0001831363    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer Yes    
ICFR Auditor Attestation Flag false    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity Small Business true    
Entity Common Stock, Shares Outstanding   115,521,157  
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Shell Company false    
Entity File Number 001-39926    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 98-1448275    
Entity Address Address Line1 1065 East Hillsdale Blvd.    
Entity Address, Address Line Two Suite 100    
Entity Address, City or Town Foster City    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94404    
City Area Code 650    
Local Phone Number 525-5535    
Entity Public Float     $ 324,170,335
Document Transition Report false    
Entity Interactive Data Current Yes    
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Trading Symbol TERN    
Security Exchange Name NASDAQ    
Document Financial Statement Error Correction [Flag] false    
Amendment Description This Amendment No. 1 on Form 10-K/A (this Amendment) is filed with respect to our Annual Report on Form 10-K for the year ended December 31, 2025 (the Original Filing), filed with the Securities and Exchange Commission (the SEC) on March 30, 2026. We are filing this Amendment for the purpose of (i) including the information required by Part III of Form 10-K, which information was omitted from the Original Filing in reliance on General Instruction G(3) to Form 10-K, which permits the information required by Part III of Form 10-K to be incorporated by reference from a registrant’s definitive proxy statement if it is filed with the SEC no later than 120 days after the fiscal year end and (ii) updating certain of our exhibits that were filed in the Original Filing.  We do not intend to file a definitive proxy statement for our 2026 annual meeting of stockholders within 120 days of the end of our fiscal year ended December 31, 2025. Accordingly, this Amendment is being filed, in part, to provide the information required by Items 10 through 14 of Part III of the Original Filing and delete the reference on the cover page of the Original Filing to the incorporation by reference of portions of our definitive proxy statement into Part III of the Original Filing. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the Exchange Act), new certifications by our principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) of the Exchange Act; accordingly, Item 15 of Part IV of the Original Filing has also been amended to reflect the filing of these new exhibits. Because no financial statements are being filed in this Amendment, and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. We are also not filing new certifications required under Section 906 of the Sarbanes-Oxley Act of 2002 or a new consent of our independent registered public accounting firm. This Amendment speaks as of the date of the Original Filing and, except as described above, this Amendment makes no changes to the Original Filing. This Amendment does not amend, update or change the financial statements or any other information presented in the Original Filing and does not otherwise reflect events occurring after the date of the Original Filing. Accordingly, this Amendment should be read in conjunction with our filings with the SEC subsequent to the filing of the Original Filing. Unless indicated otherwise, throughout this Amendment, references to the “Company,” “Terns,” “we,” “us,” and “our” refer to Terns Pharmaceuticals, Inc. and its consolidated subsidiaries.